Abstract: The present invention relates to a composition for preventing, improving, or treating diseases related to advanced glycation end products, comprising an indole derivative or a pharmaceutically acceptable salt thereof. Specifically, the composition of the present invention possesses the effect of trapping methylglyoxal (MGO), which is a main precursor of advanced glycation end products, and thus can be effectively used for preventing, improving, or treating diseases related to advanced glycation end products.

Abstract: An encapsulant composition for an optical device; comprises an ethylene/alpha-olefin copolymer having high volume resistance and light transmittance. An encapsulant film for an optical device using the same is also provided.

Abstract: The present invention relates to a novel indole derivative and a use thereof. The novel indole derivative according to the present invention traps methylglyoxal (MGO), which is a main precursor of advanced glycation end products, and thus can be effectively used for preventing, improving, or treating diseases related to advanced glycation end products.

Abstract: An image sensing device includes: a control circuit coupled between an output terminal of a pixel signal and a high voltage terminal, and configured to generate a control voltage corresponding to a voltage level of the pixel signal; and a current supplying circuit coupled between the output terminal and the high voltage terminal, and configured to supply a pre-charge current, which is configured to be adaptively adjusted according to the voltage level of the pixel signal, to the output terminal based on the control voltage.

Abstract: A display device includes a substrate including an organic film layer, a first lower pattern which is disposed on the substrate, includes overlap patterns, first bridges, and second bridges, and has a mesh shape, a second lower pattern which is disposed in a same layer as the first lower pattern, is connected to the first lower pattern, and surrounds the first lower pattern, a first active pattern disposed on the first lower pattern, and a plurality of gate electrodes disposed on the first active pattern and overlapping the overlap patterns.

Abstract: A peridynamic method having an added mirroring node according to embodiments of the present invention includes: a first step of calculating a shape tensor of a first node; a second step of calculating force state vectors of the first node and each of a plurality of second nodes by using the shape tensor; and a third step of calculating a peridynamic motion equation of the first node by using the force state vectors. The first node is a node located on a boundary of a structure and has a predetermined size horizon region, the plurality of second nodes is nodes in the horizon region, the plurality of second nodes includes one or more third nodes, and the third node is a second node having no node at a point which is origin-symmetrical based on the first node among the plurality of second nodes. In the first step, the shape tensor is calculated by using a position value in which the third node is origin-symmetrical based on the first node.

Abstract: The present invention relates to a compound capable of lowering the flammability of a non-aqueous electrolyte when included in the non-aqueous electrolyte and improving the life properties of a battery by forming an electrode-electrolyte interface which is stable at high temperatures and low in resistance, and relates to a compound represented by Formula I descried herein, a non-aqueous electrolyte solution and a lithium secondary battery both including the compound, n, m, Ak, and X are described herein.

Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: A lithium secondary battery includes a negative electrode, a positive electrode positioned opposite to the negative electrode, a separator disposed between the negative electrode and the positive electrode, and a non-aqueous electrolyte, wherein the negative electrode includes a silicon-based active material, the silicon-based active material comprises a compound represented by SiOx, wherein 0?x<2, the non-aqueous electrolyte includes a lithium salt, an organic solvent, and an additive, the additive includes a first additive and a second additive, the first additive includes a coumarin-based compound represented by Formula 1, and the second additive includes at least one of lithium fluoromalonato(difluoro)borate (LiFMDFB), lithium difluoro(oxalato)borate (LiDFOB), lithium difluorophosphate (LiDFP), or lithium difluorobis-(oxalate)phosphate (LiDFOP): wherein R and n are described herein.

Abstract: The present disclosure relates to a composition for skin improvement and a pharmaceutical composition for preventing or treating an inflammatory skin disease, the compositions including an umbilical cord-derived mesenchymal stem cell culture medium as an active ingredient. The compositions exhibit a wound relief, wrinkle improvement, regeneration, elasticity increase, moisturizing, barrier strengthening, anti-inflammatory or antioxidant effect, and thus can be effectively used as a cosmetic composition for skin improvement or a pharmaceutical composition for preventing or treating an inflammatory skin disease.

Abstract: A display device includes a substrate, a first electrode and a second electrode which are spaced apart from each other in a second direction, light-emitting elements spaced apart from each other in the first direction, a first contact electrode electrically contacting the light-emitting elements, and a second contact electrode electrically contacting the light-emitting elements. The first contact electrode electrically contacts the first electrode through a first contact portion disposed on the first electrode, the second contact electrode electrically contacts the second electrode through a second contact portion disposed on the second electrode, the first contact portion is disposed on an end portion in the first direction of the first contact electrode, and the second contact portion is disposed on an end portion in the first direction of the second contact electrode.

Abstract: A display apparatus including a light-emitting device and a method of forming the same are provided. The light-emitting device may be electrically connected to the driving circuit. A first planarization layer may be disposed on the driving circuit, a second planarization layer may be disposed on the first planarization layer, and the light-emitting device may be disposed on the second planarization layer. An upper surface of the second planarization layer toward the light-emitting device may be parallel with a surface of a device substrate supporting the light-emitting device and the driving circuit. Thus, in the display apparatus and the method of forming the same, decreasing the quality of an image due to differences in the generation position of the light emitted from the light-emitting device may be prevented.

Abstract: The present invention relates to a lung cancer model based on a normal lung organoid, prepared by fusing cancer cells to the normal lung organoid. By using the lung cancer model according to the present invention, it is possible not only to observe the progression or metastasis pattern of lung cancer from the early stage of proliferating lung cancer cells to the stage of forming a tumor but also to compare the effect of an anticancer agent at each stage, and thus the information on an appropriate therapeutic agent may be provided according to the stage of cancer development. In addition, since the lung cancer model according to the present invention includes a normal lung organoid and cancer cells, which are fused, it can be effectively used to confirm the effect of an anticancer agent on normal tissue and the effect of cancer cell-specific apoptosis.

Abstract: The present disclosure relates to an electrode rolling apparatus including a non-coating portion pressing unit that rolls a non-coating portion of an electrode substrate and an electrode rolling method using the same, and can prevent a swell from occurring in the non-coating portion region during the process of rolling the electrode substrate and increase the efficiency of the manufacturing process.

Abstract: A magnetic element according to an embodiment of the present invention a first core, a second core, a bobbin including a through-hole, the bobbin being at least partially disposed between the first core and the second core, a first coil unit and a second coil unit at least partially disposed on the bobbin, wherein at least one of the first coil unit or the second coil unit includes a plurality of conductive wires disposed around the through-hole, wherein the bobbin includes a first portion formed to allow the first end portion and the second end portion of each of the plurality of conductive wires to be disposed thereon and a second portion formed opposite the first portion in a horizontal direction, with the through-hole interposed therebetween, and wherein portions of the plurality of conductive wires overlap each other vertically on the second portion.

Abstract: A pharmaceutical composition for preventing or treating cancer, which is associated with a KRAS mutation and exhibits resistance to an EGFR-targeted therapeutic agent is disclosed. The pharmaceutical composition can be useful for treatment of patients with cancer which has the KRAS mutation and exhibits resistance to cetuximab that is an anticancer therapeutic agent. A method for providing information on an anticancer treatment and/or enhancing cancer treatment by identifying a KRAS mutation and optionally additionally a RON mutation are disclosed.

Abstract: A transformer according to one embodiment of the present invention comprises: a core unit including an upper core and a lower core; a coil unit of which a portion is disposed in the core unit; and a bobbin unit disposed between the core unit and the coil unit, wherein the coil unit includes a first coil and a second coil of which at least a portion is disposed on the side surface of the first coil, the core unit includes a first outer foot part, a second outer foot part, and an intermediate foot part disposed between the first outer foot part and the second outer foot part, and the shortest distance between the first coil and the second coil can be 0.1 to 0.3 times the shortest distance between the outermost part of the first coil and an adjacent outer foot part from among the first outer foot part and the second outer foot part.

Abstract: The present invention relates to a pharmaceutical composition comprising an agent inhibiting gene expression or protein activity of osteopontin as an active ingredient for preventing or treating neurodegenerative disease. According to the present invention, there is an effect of suppressing amyloid beta (A?)-induced neuronal cell death by downregulating the expression or activity of osteopontin. In addition, an inhibitor against the expression or activity of osteopontin decreases a level of pro-inflammatory proteins and conversely, increases a level of anti-inflammatory proteins. Therefore, it is expected that the present invention can be advantageously used as a therapeutic agent for various neurodegenerative diseases including Alzheimer's disease.

Abstract: A display apparatus including color filters is disclosed. The display apparatus may comprise a device substrate including pixel areas. A light-emitting device may be disposed on each pixel area. An encapsulating layer covering the light-emitting devices may be disposed on the device substrate. The color filters may be disposed on the encapsulating layer. For example, separating dams defining openings overlapping with the light-emitting devices may be disposed on the encapsulating layer. The pixel areas disposed in a first direction may display the same color. Some of the separating dams extending in a second direction that is different from the first direction between the pixel areas may have a relatively short length. Thus, in the display apparatus, the volume difference between the color filters may be reduced.

Abstract: A touch display device includes light emitting devices disposed on a substrate, an encapsulation unit disposed on the light emitting devices, a touch buffer film disposed on the encapsulation unit, second bridge electrodes disposed on the touch buffer film, a black matrix disposed on the touch buffer film and including openings, color filters that fill the openings, and a cover layer disposed on the color filters and the black matrix.